Glaxo Sales Drop As FDA Hearings Approach

Law360, New York (July 25, 2007, 12:00 AM EDT) -- The troubles over GlaxoSmithKline PLC's diabetes drug, Avandia, have just been compounded in the days leading up to a U.S. Food and Drug Administration advisory hearing over its safety.

Even as the company is preparing for the FDA hearing on July 30, it announced that sales of the drug have dropped precipitously. Meanwhile, two U.S. Senators have come forward alleging the FDA senior official was sidelined for voicing concerns about the drug.

The series of problems come after an article published in the New England Journal...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.